منابع مشابه
Antimalaria Drug Development & Pipeline
Artemisin traditionally cleave the peroxide bond by Fe(II) found in heme proteins, thus generating toxic oxygen radicals. Synthetic peroxides, thus are proving to be useful substitutes for artemisinin. The first-generation ozonide OZ277, known as arterolane [1], has been found to inhibit the growth of chloroquine-resistant (K1) and chloroquine sensitive (NF54) parasite strains. In 2012, the com...
متن کاملCYP2C8 and antimalaria drug efficacy.
Malaria is a major infectious disease. In the last 10 years it has killed more than 20 million people, mainly small children in Africa. The highly efficacious artemisinine combination therapy is being launched globally, constituting the main hope for fighting the disease. Amodiaquine is a main partner in these combinations. Amodiaquine is almost entirely metabolized by the polymorphic cytochrom...
متن کاملAntimalaria drug offers antitumor strategies.
Q uinacrine, an old antimalaria drug given to millions of soldiers during World War II, is garnering new interest as a chemotherapeutic agent that targets two major cancer-promoting pathways — apparently with minimal toxicity to normal cells.Interest in the drug’s mechanism of action has also spawned a search for structural analogues culminating in a new class of compounds, dubbed curaxins, whi...
متن کاملAlzheimer's drug-development pipeline: 2016
BACKGROUND Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptom...
متن کاملAlzheimer's disease drug development pipeline: 2017
INTRODUCTION There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017. RESULTS There are 105 agents in the AD treatment development pipeline, of which 25 agents...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Analytical & Pharmaceutical Research
سال: 2017
ISSN: 2473-0831
DOI: 10.15406/japlr.2017.05.00136